Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy.

Clinical immunology (Orlando, Fla.) - 1 Jun 2017

Lee Silvia, Laiman Alfred, French Martyn A, Flexman James, Watson Mark W, Price Patricia

Abstract excerpt

Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a median (range) interval of 597 (186-766) weeks. Prior to ART, HIV/HCV patients had lower levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive neutralising antibodies (nAb) titres, than HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibodies, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4-Positive T-Lymphocytes

Share to CD8-Positive T-Lymphocytes

Share to Hepatitis C

Share to Immunoglobulin G

Share to Lymphocyte Count

Source

Identifiers

PMID: 28315414
DOI: 10.1016/j.clim.2017.03.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy.PMID 28315414Read ↗

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy.Semantic proximity Read ↗

Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.Semantic proximity Read ↗

Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.Semantic proximity Read ↗

Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses.Semantic proximity Read ↗

Antibody- and genome-based identification of recent HCV infection.Semantic proximity Read ↗

Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.Semantic proximity Read ↗

Viral Rebound Kinetics Correlate with Distinct HIV Antibody FeaturesSemantic proximity Read ↗

HIV-1 envelopes from virions that persist in plasma on antiretroviral therapy show reduced susceptibility to autologous immunoglobulins and variable sensitivity to broadly neutralizing monoclonal antibodiesSemantic proximity Read ↗

Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.Semantic proximity Read ↗

Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon.Semantic proximity Read ↗

Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.Semantic proximity Read ↗

Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.